FDA approvals - December 2025
The winter batch of FDA approvals featured therapies that compress intervention into fewer doses, fewer visits, and fewer points of failure.
The winter batch of FDA approvals featured therapies that compress intervention into fewer doses, fewer visits, and fewer points of failure.
Mitochondrial disease and mutant leukemias signal where specialty pharma is placing its biggest bets.
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
All the details on when the 44th annual J.P. Morgan Healthcare Conference takes place!
"We call it the post-COVID storm. Inflation, tariffs, interconnection delays - it’s never been harder to deliver fixed-price projects with long lifecycles,” Tristan Grimbert explains how EDF power solutions is navigating today’s volatile energy economics.
"The beating heart and soul of this movement are smaller- and medium-sized enterprises,” Kylie Nealis explains how B Lab™ is raising the bar for business standards in climate justice.
“We can make fully renewable, even carbon-negative gasoline - but the market isn’t built for it yet.” Verde Clean Fuels is transforming wasted energy into profit while cutting lifecycle emissions by up to 35%.
“This is the first time in hydro history that there is no compromise between biodiversity and power production.” Bill Malus explains how Natel Energy’s FishSafe™ turbines deliver 98–100% fish survival without sacrificing efficiency.
“We started with a mission to enable electric freedom for EVs.” Fastned's CEO, Michiel Langezaal, on prime locations, long-term vision, and the need for dependable charging to accelerate Europe’s transition toward faster, more accessible electric mobility.
“It’s electricity-free, non-toxic, reusable - and you recharge it with just a coffee mug’s worth of water,” Tiffany Yeh unveils Eztia's cost-effective solution to overheating - common reagents.